RTW INVESTMENTS, LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1493215.
- Reported value$11.71bn
- Positions84
Holdings: 84 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals IncMDGL | COM | 558868105 | 1,071 | 9.1% | 1,993,687 | Unchanged | |
| Argenx SEARGX | SPONSORED ADR | 04016X101 | 658 | 5.6% | 709,446 | Unchanged | |
| PTC Therapeutics IncPTCT | COM | 69366J200 | 632 | 5.4% | 7,746,415 | Unchanged | |
| Protagonist Therapeutics IncPTGX | COM | 74366E102 | 620 | 5.3% | 5,061,175 | Added+2,122 | |
| CG Oncology IncCGON | COM | 156944100 | 605 | 5.2% | 8,514,590 | Added+1,529,782 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 516 | 4.4% | 4,842,880 | Unchanged | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 435 | 3.7% | 13,900,620 | Added+600,000 | |
| Spyre Therapeutics IncSYRE | COM NEW | 00773J202 | 377 | 3.2% | 4,251,996 | Added+80,000 | |
| Celcuity IncCELC | COM | 15102K100 | 346 | 3.0% | 3,304,903 | Added+265,282 | |
| Erasca IncERAS | COM | 29479A108 | 329 | 2.8% | 17,946,754 | Added+1,789,579 | |
| Radnet IncRDNT | COM | 750491102 | 299 | 2.6% | 4,846,958 | Added+561,958 | |
| Oruka Therapeutics IncORKA | COM | 687604108 | 299 | 2.6% | 3,139,030 | Added+1,080,882 | |
| Natera IncNTRA | COM | 632307104 | 271 | 2.3% | 1,000,000 | Reduced−250,000 | |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 260 | 2.2% | 7,796,895 | Added+4,148,100 | |
| Irhythm Holdings IncIRTC | COM | 450056106 | 260 | 2.2% | 2,182,631 | Added+514,131 | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 244 | 2.1% | 2,862,003 | Added+140,845 | |
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 237 | 2.0% | 10,776,820 | New+10,776,820 | |
| Establishment Labs Holdings Inc | COM | G31249108 | 228 | 1.9% | 2,655,695 | Unchanged | |
| Guardant Health IncGH | COM | 40131M109 | 222 | 1.9% | 1,481,033 | Unchanged | |
| Neurocrine Biosciences IncNBIX | COM | 64125C109 | 214 | 1.8% | 1,267,925 | Added+205,853 | |
| Tarsus Pharmaceuticals IncTARS | COM | 87650L103 | 211 | 1.8% | 3,357,059 | Added+11,034 | |
| Stoke Therapeutics IncSTOK | COM | 86150R107 | 184 | 1.6% | 5,623,525 | Unchanged | |
| Uniqure NV | SHS | N90064101 | 182 | 1.5% | 3,941,572 | Added+1,355,216 | |
| Acadia Pharmaceuticals IncACAD | COM | 004225108 | 181 | 1.5% | 7,144,524 | Unchanged | |
| Repligen CorpRGEN | COM | 759916109 | 169 | 1.4% | 1,240,637 | Added+34,637 | |
| Urogen Pharma Ltd | COM | M96088105 | 167 | 1.4% | 4,543,895 | Unchanged | |
| GH Research plc | ORDINARY SHARES | G3855L106 | 160 | 1.4% | 5,933,815 | Unchanged | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 155 | 1.3% | 4,869,798 | Unchanged | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 151 | 1.3% | 10,700,974 | Added+68,584 | |
| Immatics N.V | SHS | N44445109 | 131 | 1.1% | 12,946,176 | Added+76,836 | |
| ZAI Lab LtdZLAB | ADR | 98887Q104 | 125 | 1.1% | 6,574,032 | Unchanged | |
| Immunovant IncIMVT | COM | 45258J102 | 122 | 1.0% | 3,177,849 | Unchanged | |
| Belite Bio IncBLTE | SPONSORED ADS | 07782B104 | 110 | 0.9% | 715,332 | Unchanged | |
| Xencor IncXNCR | COM | 98401F105 | 109 | 0.9% | 6,777,461 | Unchanged | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 92.3 | 0.8% | 13,560,258 | Reduced−119,990 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 89.4 | 0.8% | 2,309,021 | Reduced−3,149,654 | |
| Alkermes plc | SHS | G01767105 | 87.6 | 0.7% | 1,672,356 | Unchanged | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 86.3 | 0.7% | 1,607,507 | New+1,607,507 | |
| Replimune Group IncREPL | COM | 76029N106 | 82.0 | 0.7% | 7,411,581 | Added+54,665 | |
| Castle Biosciences IncCSTL | COM | 14843C105 | 66.3 | 0.6% | 2,778,335 | Added+20,000 | |
| Candel Therapeutics IncCADL | COM | 137404109 | 66.1 | 0.6% | 6,422,018 | Unchanged | |
| Rocket Pharmaceuticals IncRCKT | COM | 77313F106 | 60.5 | 0.5% | 17,687,772 | Unchanged | |
| Kodiak Sciences IncKOD | COM | 50015M109 | 58.0 | 0.5% | 1,487,934 | Unchanged | |
| Aktis Oncology IncAKTS | COM | 01021M104 | 51.3 | 0.4% | 1,592,043 | Unchanged | |
| Axogen IncAXGN | COM | 05463X106 | 46.7 | 0.4% | 1,011,576 | New+1,011,576 | |
| Danaher Corp DelDHR | COM | 235851102 | 43.8 | 0.4% | 230,000 | New+230,000 | |
| Cullinan Therapeutics IncCGEM | COM | 230031106 | 43.1 | 0.4% | 2,364,347 | Added+658,387 | |
| Neurogene IncNGNE | COM | 64135M105 | 42.8 | 0.4% | 1,362,456 | Unchanged | |
| Hinge Health IncHNGE | CL A | 433313103 | 41.5 | 0.4% | 500,000 | Reduced−1,430,000 | |
| Orchestra Biomed Holdings IncOBIO | COM | 68572M106 | 41.2 | 0.4% | 9,556,063 | Added+1,250,000 | |
| Solid Biosciences IncSLDB | COM NEW | 83422E204 | 38.9 | 0.3% | 3,892,926 | New+3,892,926 | |
| Savara IncSVRA | COM | 805111101 | 36.7 | 0.3% | 5,952,380 | Unchanged | |
| Aquestive Therapeutics IncAQST | COM | 03843E104 | 30.9 | 0.3% | 7,426,471 | Unchanged | |
| Kymera Therapeutics IncKYMR | COM | 501575104 | 27.5 | 0.2% | 240,000 | Unchanged | |
| Verastem IncVSTM | COM NEW | 92337C203 | 25.3 | 0.2% | 6,635,793 | Added+59,487 | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 24.2 | 0.2% | 248,063 | Unchanged | |
| Beta Bionics IncBBNX | COM | 08659B102 | 23.5 | 0.2% | 1,500,000 | Reduced−500,000 | |
| Century Therapeutics IncIPSC | COM | 15673T100 | 21.3 | 0.2% | 8,695,652 | Unchanged | |
| Evommune IncEVMN | COM SHS | 30054Y107 | 20.0 | 0.2% | 1,502,235 | Unchanged | |
| Beam Therapeutics IncBEAM | COM | 07373V105 | 19.6 | 0.2% | 570,394 | Unchanged | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 18.8 | 0.2% | 400,000 | Added+100,000 | |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 13.8 | 0.1% | 370,370 | New+370,370 | |
| Ataibeckley Inc | COM SHS | 04650F101 | 10.5 | <0.1% | 2,000,000 | Unchanged | |
| Milestone Pharmaceuticals inMIST | COM | 59935V107 | 10.5 | <0.1% | 7,833,336 | Added+1,502,335 | |
| Ocugen IncOCGN | COM | 67577C105 | 10.2 | <0.1% | 6,666,666 | Unchanged | |
| Tenax Therapeutics IncTENX | COM NEW | 88032L605 | 10.1 | <0.1% | 696,570 | Added+326,324 | |
| Heartflow IncHTFL | COM | 42238D107 | 8.7 | <0.1% | 295,000 | Reduced−200,000 | |
| Perceptive Cap Solutions Cor | CL A ORD SHS | G70077105 | 8.1 | <0.1% | 742,500 | Unchanged | |
| Wave Life Sciences Ltd | SHS | Y95308105 | 7.8 | <0.1% | 1,350,000 | Unchanged | |
| Larimar Therapeutics IncLRMR | COM | 517125100 | 7.8 | <0.1% | 2,565,999 | Added+1,065,999 | |
| Lumexa Imaging Holdings IncLMRI | COM | 550249106 | 7.3 | <0.1% | 650,000 | Unchanged | |
| Allogene Therapeutics IncALLO | COM | 019770106 | 6.8 | <0.1% | 3,250,000 | New+3,250,000 | |
| Crescent Biopharma Inc. | COM | G2545C104 | 6.7 | <0.1% | 372,856 | Unchanged | |
| 4D Molecular Therapeutics inFDMT | COM | 35104E100 | 6.3 | <0.1% | 475,737 | Unchanged | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 6.3 | <0.1% | 212,000 | New+212,000 | |
| Capricor Therapeutics IncCAPR | COM NEW | 14070B309 | 6.0 | <0.1% | 250,000 | Unchanged | |
| Kalaris Therapeutics IncKLRS | COM | 482929106 | 5.3 | <0.1% | 1,300,000 | Unchanged | |
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 3.5 | <0.1% | 26,400 | New+26,400 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 3.2 | <0.1% | 175,000 | Reduced−681,962 | |
| Medline IncMDLN | COM CL A | 58507V107 | 2.8 | <0.1% | 70,000 | Unchanged | |
| Disc Medicine IncIRON | COM | 254604101 | 2.2 | <0.1% | 30,000 | Unchanged | |
| Imagenebio IncIMA | COM | 45175G207 | 2.0 | <0.1% | 334,445 | Unchanged | |
| Exagen IncXGN | COM | 30068X103 | 0.9 | <0.1% | 195,000 | Reduced−200,231 | |
| Rocket Pharmaceuticals Inc | *W EXP 09/02/202 | 77313F114 | 0.0 | <0.1% | 350,000 | Unchanged |
Sold out: 13 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | COM | 03753U106 | 0.0 | 0.0% | 0 | Sold out−3,685,045 | |
| Apogee Therapeutics Inc | COM | 03770N101 | 0.0 | 0.0% | 0 | Sold out−2,782,097 | |
| Arrowhead Pharmaceuticals inARWR | COM | 04280A100 | 0.0 | 0.0% | 0 | Sold out−585,682 | |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−2,054,175 | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 0.0 | 0.0% | 0 | Sold out−4,186,599 | |
| Crinetics Pharmaceuticals in | COM | 22663K107 | 0.0 | 0.0% | 0 | Sold out−1,451,326 | |
| Fulgent Genetics IncFLGT | COM | 359664109 | 0.0 | 0.0% | 0 | Sold out−1,289,000 | |
| Intuitive Surgical IncISRG | COM NEW | 46120E602 | 0.0 | 0.0% | 0 | Sold out−220,000 | |
| Inventiva SAIVA | ADS | 46124U107 | 0.0 | 0.0% | 0 | Sold out−1,298,702 | |
| Jade Biosciences IncJBIO | COM NEW | 008064206 | 0.0 | 0.0% | 0 | Sold out−573,205 | |
| Omada Health IncOMDA | COM | 68170A108 | 0.0 | 0.0% | 0 | Sold out−200,000 | |
| Stryker CorporationSYK | COM | 863667101 | 0.0 | 0.0% | 0 | Sold out−100,000 | |
| Waystar HLDG CorpWAY | COM | 946784105 | 0.0 | 0.0% | 0 | Sold out−1,630,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001493215-26-000164 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.